+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06533826

Phase 2 Trial of Sequential Trastuzumab Deruxtecan and Datopotamab Deruxtecan in HER2-negative Metastatic Breast Cancer After Prior ADC Therapy

Led by Ana C Garrido-Castro, MD · Updated on 2026-08-26

357

Participants Needed

11

Research Sites

552 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of two investigational antibody drug conjugates, trastuzumab deruxtecan and datopotamab deruxtecan, in treating HER2-negative HER2-low or HER2-0 metastatic breast cancer. This phase 2, open-label trial involves patients with locally advanced unresectable or metastatic breast cancer who have progressed on prior antibody drug conjugate therapy. The study aims to understand how sequential treatment with these drugs works by switching the target of the antibody drug conjugate. Participants will be assigned randomly to one of four treatment arms receiving either trastuzumab deruxtecan or datopotamab deruxtecan, divided by hormone receptor status. If disease progresses, they may crossover to receive the other drug in a second group of treatment arms. Some patients may enroll directly to the second group if they have already received the first drug. Treatments are given in 21-day cycles with dosing on Day 1, and imaging is conducted every 9 weeks. Study drugs are provided via intravenous infusion as per protocol. Participants will undergo screening, treatment visits, blood tests, tumor biopsies, ECGs, echocardiograms, CT and MRI scans, and eye exams. Tumor biopsies occur at baseline, between Cycle 2 Day 1 and Day 8, and at progression. After treatment ends, follow-up visits occur approximately every six months. The main outcomes measured include objective response rates and progression-free survival, with monitoring continuing up to 36 months or longer for overall survival and quality of life assessments.

CONDITIONS

Brief Title

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

Research Team

A

Ana Garrido-Castro, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here